Latest news

New data released today (Tuesday, 10th November) shows that nearly half (45 per cent) of pancreatic cancer cases in 2013 were diagnosed as a result of an emergency presentation at hospital. This is more than double the average rate of 20 per cent for all other cancer types.

We are outraged that as of today, (Wednesday 4th November), the life-extending drug Abraxane is no longer available to newly eligible patients with advanced pancreatic cancer in England through the Cancer Drugs Fund (CDF). 

On the first day of Pancreatic Cancer Awareness Month, Pancreatic Cancer UK announces it will fund over £1 million of ground breaking research into treatments for pancreatic cancer which could mean a longer life for thousands of people. 

New research into the development of a potential new immunotherapy treatment for pancreatic cancer has been reported today in the media.

The National Institute for Health and Care Excellence (NICE) has today (Thursday, 17th September) announced it will not allow advanced pancreatic cancer patients in England routine access to the life-extending drug Abraxane on the NHS.